Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed (Nasdaq: OBIO) announced that its Board’s Compensation Committee granted stock options to purchase an aggregate of 85,500 common shares to five newly hired employees on June 1, 2026.
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) announced that its Board’s Compensation Committee granted stock options to purchase an aggregate of 85,500 common shares to five newly hired employees on June 1, 2026.
The options, issued under the 2025 New Hire Inducement Plan, will vest over four years and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
Details
News Market Reaction – OBIO
In the Jun 3 session, OBIO declined 1.28%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Inducement options
- 85,500 shares
- Stock options granted to five newly hired employees on June 1, 2026
- New employees
- 5 employees
- Recipients of inducement stock option grants
- Vesting period
- 4 years
- Vesting schedule for the inducement stock options
- Listing rule
- Nasdaq Rule 5635(c)(4)
- Basis for granting inducement equity awards
- Registered shares
- 8,027,890 shares
- Common stock covered by resale registration statement
- Potential warrant proceeds
- $7.3 million
- Maximum cash proceeds if Ligand warrant exercised at $3.67
- Ligand warrant strike
- $3.67 per share
- Exercise price referenced in resale shelf summary
- Current share price
- $3.83
- Pre-news trading level vs 200-day MA of $3.88
Historical Context
-
Announced participation in Jefferies Global Healthcare Conference with webcast access.
-
Reported Q1 2026 results, cash runway into Q4 2027, and trial progress.
-
Updated BACKBEAT pivotal trial timelines and FDA-approved sample size reduction.
-
Received $15M tranche from Ligand, bringing capital from Ligand to $40M.
-
Received $20M from Medtronic under financing agreement to support BACKBEAT Trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on June 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 85,500 shares of the Company’s common stock to five newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Orchestra Biomed, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options granted to each new employee will vest over a four-year period.
Orchestra Biomed is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.